Pharmafile Logo
Pharmafocus logo
Advanced Search

Kanuma

Showing 2 posts of 2 posts found.

More evidence required for Alexion’s Kanuma, says NICE

February 18, 2016
Medical Communications, Research and Development Alexion, Kanuma, LAL-D, rare diseases

NICE says it needs additional trial data before it can recommend Alexion’s enzyme replacement therapy Kanuma (sebelipase alfa) for the …

News
Alexion sign

Alexion scores double EU approval

September 1, 2015
Manufacturing and Production, Sales and Marketing Alexion, EC, European Commission, Kanuma, Strensiq, asfotase alfa, sebelipase alfa, ultra rare disease, ultra-rare disease

Two treatments developed by ultra-rare disease specialists Alexion Pharmaceuticals are now approved for use in Europe. The European Commission approved …

News
The Gateway to Local Adoption Series

Latest content

Cori Clinical raises US$4m to expand AI platform for clinical trial design

October 14, 2026

Ofichem acquires US drug substance CDMO Kinentia

October 14, 2026

Jager-van Dijk is new Arletta Pharma Solutions CEO 

October 13, 2026

Tridem begins phase Ib trial of Parkinson’s disease vaccine

October 13, 2026

Bio-Techne opens GMP small-molecule manufacturing facility in Bristol

October 13, 2026